Sermorelin, IGF-1 and Cancer Risk: The Honest Position
Every page selling a growth-hormone peptide lists what it may improve. Almost none of them address the question a careful person asks next: growth hormone makes things grow — what about the things you do not want growing?
It is the right question. This page answers it as far as the evidence allows for sermorelin, which is not as far as either the sellers or the alarmists claim.
The chain: sermorelin, growth hormone, IGF-1
Sermorelin does not contain growth hormone. It is a fragment of the hormone that tells the pituitary to release growth hormone, in pulses, the way the body does it. Growth hormone then acts largely by prompting the liver to make insulin-like growth factor 1 — IGF-1 — which is the molecule that does most of the tissue-building work, and the one that is measured to see whether sermorelin is doing anything.
IGF-1 is a growth signal. It promotes cell division and discourages the programmed cell death that clears damaged cells. Those are exactly the properties a cancer benefits from, and that is not a theoretical concern.
What the epidemiology shows
Large cohort studies have consistently found that people with higher circulating IGF-1 — within the normal range, not from treatment — have modestly higher rates of several cancers over the following years. The associations are best established for prostate, breast and colorectal cancer. The size of the effect is modest: in the pooled analyzes, moving from the lower to the upper part of the normal range is associated with something in the region of a 20–40% relative increase.
At the extremes, the picture sharpens. People with acromegaly — a pituitary tumor that produces growth hormone in excess for years — have clearly raised rates of colorectal and some other cancers. People with a rare genetic condition that leaves them unable to respond to growth hormone have strikingly low cancer rates.
So the direction is not in doubt. More IGF-1, over time, means somewhat more cancer risk at the population level.
What the epidemiology does not show
It does not show that raising IGF-1 with a secretagogue, in an adult whose level had fallen with age, produces the risk that a lifelong high level is associated with. That has not been studied, because nobody has run a trial of sermorelin large enough or long enough to count cancers. The trials that exist were small, short, and measured body composition.
It does not show what happens with pulsatile stimulation — sermorelin's mode — as opposed to the continuous high exposure of acromegaly. There is a physiological argument that pulses are safer, because the body's own feedback stays intact. It is an argument, not a result.
And it does not apply to sermorelin's sublingual route at all, because — as the main page says plainly — that route has no published human data of any kind.
The honest summary: sermorelin raises a hormone that is associated with cancer risk at the population level; whether restoring an age-lowered level to a mid-range one adds risk is unknown; and the absence of evidence of harm reflects the absence of studies, not the presence of safety.
What that means at ACT 2
Active cancer is an absolute exclusion. Any current malignancy, or one under active surveillance, rules sermorelin out. There is no version of "restore IGF-1" that is appropriate in a person with a tumor that may respond to it.
A history of cancer is a conversation with the oncologist, not with us alone, and for hormone-responsive cancers — prostate, breast — the default is no.
IGF-1 is measured at baseline and on treatment, and we do not push it above the mid-range for age. A level at the top of the reference range is not a goal; it is a reason to reconsider. The IGF-1 page covers what the number means.
Age-appropriate cancer screening continues — colonoscopy, PSA discussion, mammography — on schedule. Sermorelin is a reason to be current on all of it.
And, as the main page says, we will not describe sermorelin as anti-aging. The cancer question is one of the reasons.
Frequently asked questions
No study has shown that it does, and no study has been large or long enough to show that it does not. It raises IGF-1, which is associated with modestly higher cancer risk at the population level.
IGF-1 promotes cell growth and discourages cell death. Large cohorts find higher IGF-1 within the normal range associated with higher rates of prostate, breast and colorectal cancer over time.
Active cancer is an absolute exclusion. A history of cancer is a decision made with your oncologist, and for hormone-responsive cancers the default is no.
Physiologically, pulsatile stimulation with intact feedback is expected to be safer than continuous high exposure. That expectation has not been tested in outcome studies.
Yes — at baseline and on treatment, and we do not aim above the mid-range for age.
You should be current on age-appropriate screening regardless. Sermorelin is a reason to make sure you are.
Where this fits in your plan
The Sermorelin ODT page covers the product and its evidence; the peptide therapy page explains why peptides are rarely the first move. A baseline panel including IGF-1, and current screening, come first.
We measure first. Then we act.
References
- Renehan AG et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. The Lancet 2004;363:1346–1353.
- Knuppel A et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyzes in UK Biobank. Cancer Research 2020;80:4004–4012.
- Guevara-Aguirre J et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine 2011;3:70ra13.
- Dal J et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. Journal of Clinical Endocrinology & Metabolism 2018;103:2182–2188.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews 2018;6:45–53.
- Geref (sermorelin acetate) prescribing information (historical, discontinued 2008) — contraindications.
- Back toSermorelin ODT
- IGF-1 on sermorelinIGF-1 is the blood test that shows whether sermorelin is doing anything. What it measures, why it stands in for growth hormone, how age changes the range, and what a rise does and does not tell you.Read
- Are peptides safe?An honest, evidence-led look at peptide safety — what's known, what isn't, the biggest risk factors, and why sourcing and oversight matter most.Read
- Galleri: what the numbers sayA GRAIL laboratory-developed blood test that screens for a shared cancer signal across many cancer types.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.